cetrelimab, JNJ-63723283
63723283LUC1001
Phase 2 small_molecule active
Quick answer
cetrelimab, JNJ-63723283 for Advanced Stage Solid Tumors is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Advanced Stage Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active